Revista de enfermedades coronarias

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Abstract

Lindsay Bond

Thrombosis and inflammation may play a role in morbidity and mortality in coronavirus patients in 2019. Therapeutic-dose anticoagulation, we expected, would enhance outcomes in critically ill Covid-19 patients. Coronavirus disease 2019 (Covid-19) is linked to thrombosis and inflammation. Despite receiving standard-dose pharmacologic thromboprophylaxis, critically ill patients on Covid-19 are at increased risk of thrombosis. Systemic inflammation and coagulation activation indicators in circulation. As a result, inflammation and thrombosis may play a role in poor outcomes